1y return+71.8%S&P 500 +20.9%
3y return+124.2%S&P 500 +68.5%
5y return−55.4%S&P 500 +74.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since June 30, 2020: $45 against $242 in the S&P 500.2
NEA Management Company, LLCS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| TRVITrevi Therapeutics, Inc. | $246.6M | 15.5% | |
| MBXMBX Biosciences, Inc. | $199.5M | 12.6% | |
| GLUEMonte Rosa Therapeutics, Inc. | $186.2M | 11.7% | |
| CELCCelcuity Inc. | $179.0M | 11.3% | −25.2% |
| SGPSpyglass Pharma, Inc. | $164.6M | 10.4% | |
| SVRASavara, Inc. | $150.7M | 9.5% | |
| ZBIOZenas BioPharma, Inc. | $102.1M | 6.4% | |
| COURCoursera, Inc. | $72.6M | 4.6% | |
| AUPHAurinia Pharmaceuticals, Inc. | $67.4M | 4.2% | |
| CRISPR Therapeutics AGCUSIP H17182108 | $57.7M | 3.6% | |
| ORICORIC Pharmaceuticals, Inc. | $44.6M | 2.8% | |
| PHATPhathom Pharmaceuticals, Inc. | $21.3M | 1.3% | |
| KRROKorro Bio, Inc. | $17.1M | 1.1% | |
| X4 Pharmaceuticals, Inc.CUSIP 98420X103 | $15.1M | 1.0% | |
| CSBRChampions Oncology, Inc. | $10.6M | 0.7% | |
| NKTXNkarta, Inc. | $10.1M | 0.6% | |
| CVRXCVRx, Inc. | $10.0M | 0.6% | −3.5% |
| BDTXBlack Diamond Therapeutics, Inc. | $8.2M | 0.5% | |
| KPTIKaryopharm Therapeutics Inc. | $5.6M | 0.4% | New |
| IVAInventiva SA | $5.5M | 0.3% | |
| LONALeonaBio, Inc. | $4.3M | 0.3% | |
| Senti Biosciences, Inc.CUSIP 81726A209 | $4.2M | 0.3% | |
| MRKRMarker Therapeutics, Inc. | $2.4M | 0.2% | |
| OKUROnKure Therapeutics, Inc. | $2.2M | 0.1% | |
| IMAImageneBio, Inc. | $295K | 0.0% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| SVRASavara, Inc. | March 31, 2021 | +196.1% | $150.7M |
| TRVITrevi Therapeutics, Inc. | June 30, 2020 | +183.4% | $246.6M |
| MBXMBX Biosciences, Inc. | September 30, 2024 | +112.5% | $199.5M |
| ZBIOZenas BioPharma, Inc. | September 30, 2024 | +50.0% | $102.1M |
| LONALeonaBio, Inc. | December 31, 2025 | +21.4% | $4.3M |
| GLUEMonte Rosa Therapeutics, Inc. | June 30, 2021 | +6.6% | $186.2M |
| AUPHAurinia Pharmaceuticals, Inc. | June 30, 2020 | +4.4% | $67.4M |
| SGPSpyglass Pharma, Inc. | March 31, 2026 | −14.1% | $164.6M |
| ORICORIC Pharmaceuticals, Inc. | March 31, 2024 | −21.2% | $44.6M |
| PHATPhathom Pharmaceuticals, Inc. | June 30, 2023 | −24.2% | $21.3M |
Sold off last quarter
- Arcellx, Inc.CUSIP 03940C100 was $349.7M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +3.2% | +14.8% |
| March 31, 2026 | +2.5% | −4.6% |
| December 31, 2025 | +18.0% | +2.4% |
| September 30, 2025 | +37.7% | +7.8% |
| June 30, 2025 | +16.0% | +10.5% |
| March 31, 2025 | −2.1% | −4.6% |
| December 31, 2024 | −3.2% | +2.1% |
| September 30, 2024 | +26.0% | +5.4% |
| June 30, 2024 | −23.8% | +4.0% |
| March 31, 2024 | +5.3% | +10.0% |
| December 31, 2023 | +19.7% | +11.2% |
| September 30, 2023 | −1.9% | −3.6% |
| June 30, 2023 | +16.2% | +8.3% |
| March 31, 2023 | −6.4% | +7.0% |
| December 31, 2022 | −2.0% | +7.1% |
| September 30, 2022 | −7.0% | −5.3% |
| June 30, 2022 | −32.8% | −16.5% |
| March 31, 2022 | −24.2% | −4.9% |
| December 31, 2021 | −42.7% | +10.7% |
| September 30, 2021 | −31.3% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: NEA Management Company, LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1512848&type=13F-HR&dateb=&owner=include&count=40CIK 1512848
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1512848/000107261326000684/Filed August 14, 2026 · accession 0001072613-26-000684